Shopping Cart
Remove All
Your shopping cart is currently empty
Vudalimab
Copy Product Info
😃Good
Catalog No. T76728Cas No. 2329669-72-7
Vudalimab, a fully humanized bispecific monoclonal antibody, effectively inhibits both PD-1 and CTLA-4 immune checkpoint receptors. This dual action facilitates the selective activation of T-cells targeting tumors.
Vudalimab
Vudalimab
Copy Product Info😃Good
Catalog No. T76728Cas No. 2329669-72-7
Vudalimab, a fully humanized bispecific monoclonal antibody, effectively inhibits both PD-1 and CTLA-4 immune checkpoint receptors. This dual action facilitates the selective activation of T-cells targeting tumors.
| Pack Size | Price | USA Warehouse | Global Warehouse | Quantity |
|---|---|---|---|---|
| 1 mg | $247 | - | In Stock | |
| 5 mg | $645 | - | In Stock | |
| 10 mg | $987 | - | In Stock | |
| 25 mg | Preferential | - | In Stock |
Add to Cart
Add to Quotation
In Stock Estimated shipping dateUSA Warehouse[1-2 days] Global Warehouse[5-7 days]
With extensive experience in compound synthesis, we can provide rapid custom synthesis services for this product according to your research needs.
All TargetMol products are for research purposes only and cannot be used for human consumption. We do not provide products or services to individuals. Please comply with the intended use and do not use TargetMol products for any other purpose.
Batch Information
Select Batch
Purity:>95% (SDS-PAGE); 98.93% (SEC-HPLC)
Appearance:Liquid
Color:Transparent
Contact us for more batch information
Resource Download
Product Introduction
Bioactivity
Related Conjugates and Formulations
Antigen Details
Chemical Properties
Antibody Information
Storage & Solubility Information
| Description | Vudalimab, a fully humanized bispecific monoclonal antibody, effectively inhibits both PD-1 and CTLA-4 immune checkpoint receptors. This dual action facilitates the selective activation of T-cells targeting tumors. |
| In vitro | Vudalimab has binding avidity and can promote T cell activation, including IL-2, CD45+ cells, and IFNγ[1]. |
| In vivo | Vudalimab (administered every 2 days for 16 consecutive days. NSG mice were first engrafted with KG1a-luc cells, followed by engraftment with human peripheral blood mononuclear cells) enhances allogeneic anti-tumor responses in mice [1]. |
| Reactivity | Human |
| Verified Activity | Immobilized Human PD-1 Protein (hFc) at 8 μg/mL can bind Vudalimab. The EC50 is 0.08912 μg/mL.
Immobilized Human CTLA4 Protein (His) at 2 μg/mL can bind Vudalimab. The EC50 is 0.3927 μg/mL.   |
| Application | Functional assay |
| Antibody Type | Monoclonal |
| Formulation | Supplied as a sterile solution in a buffered formulation system (e.g., phosphate-, citrate-, or amino acid-based). Please refer to the CoA for lot-specific composition. |
| Endotoxin | <1.0 EU/mg |
| Conjucates | Unconjugated |
| Gene ID | |
| Uniprot ID | |
| Target | PD-1 & CTLA-4 |
| Cas No. | 2329669-72-7 |
| Isotype | Human IgG1 kappa |
| Recommended Isotype Control |
| Storage | store at low temperature | store at -20°C | Shipping with blue ice/Shipping at ambient temperature. |
Calculator
Preview
Related Tags: buy Vudalimab | purchase Vudalimab | Vudalimab cost | order Vudalimab | Vudalimab in vivo | Vudalimab in vitro
Generate Quote
Catalog No.: Cas No.:
Add
| Size | Quantity | Unit Price | Amount | Operation |
|---|
Generate Quote
- TOP
Feedback
Hello! How can I help you today? 
Copyright © 2015-2026 TargetMol Chemicals Inc. All Rights Reserved.